An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
Price : $35 *
At a glance
- Drugs Paritaprevir (Primary) ; Pibrentasvir (Primary) ; Ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 17 Apr 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.